PMID- 37939613
OWN - NLM
STAT- MEDLINE
DCOM- 20231115
LR  - 20231115
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 168
DP  - 2023 Dec
TI  - Harnessing the multifunctionality of lipid-based drug delivery systems for the 
      local treatment of osteoarthritis.
PG  - 115819
LID - S0753-3322(23)01617-7 [pii]
LID - 10.1016/j.biopha.2023.115819 [doi]
AB  - Osteoarthritis (OA) is a widespread joint condition affecting millions globally, 
      presenting a growing socioeconomic burden thus making the development of more 
      effective therapeutic strategies crucial. This review emphasizes recent 
      advancements in lipid-based drug delivery systems (DDSs) for intra-articular 
      administration of OA therapeutics, encompassing non-steroidal anti-inflammatory 
      drugs, corticosteroids, small molecule disease-modifying OA drugs, and RNA 
      therapeutics. Liposomes, lipid nanoparticles, lipidic mesophases, extracellular 
      vesicles and composite systems exhibit enhanced stability, targeted delivery, and 
      extended joint retention, which contribute to improved therapeutic outcomes and 
      minimized systemic drug exposure. Although active targeting strategies hold 
      promise, further research is needed to assess their targeting efficiency in 
      physiologically relevant conditions. Simultaneously, multifunctional DDSs capable 
      of delivering combinations of distinct therapeutic classes offer synergistic 
      effects and superior OA treatment outcomes. The development of such long-acting 
      systems that resist rapid clearance from the joint space is crucial, where 
      particle size and targeting capabilities emerge as vital factors. Additionally, 
      combining cartilage lubrication properties with sustained drug delivery has 
      demonstrated potential in animal models, meriting further investigation in human 
      clinical trials. This review highlights the crucial need for direct, head-to-head 
      comparisons of novel DDSs with standard treatments, particularly within the same 
      drug class. These comparisons are essential in accurately evaluating their 
      effectiveness, safety, and clinical applicability, and are set to significantly 
      shape the future of OA therapy.
CI  - Copyright (c) 2023 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Bordon, Gregor
AU  - Bordon G
AD  - Department of Chemistry, Biochemistry and Pharmaceutical Sciences, University of 
      Bern, Bern, Switzerland.
FAU - Berenbaum, Francis
AU  - Berenbaum F
AD  - Sorbonne University, INSERM CRSA, AP-HP Saint-Antoine Hospital, Paris, France.
FAU - Distler, Oliver
AU  - Distler O
AD  - Department of Rheumatology, University Hospital Zurich, University of Zurich, 
      Zurich, Switzerland.
FAU - Luciani, Paola
AU  - Luciani P
AD  - Department of Chemistry, Biochemistry and Pharmaceutical Sciences, University of 
      Bern, Bern, Switzerland. Electronic address: paola.luciani@unibe.ch.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231106
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Lipids)
SB  - IM
MH  - Animals
MH  - Humans
MH  - *Drug Delivery Systems
MH  - *Osteoarthritis/drug therapy
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Treatment Outcome
MH  - Lipids/therapeutic use
OTO - NOTNLM
OT  - Cartilage lubrication
OT  - Intra-articular drug delivery
OT  - Lipid-based drug delivery systems
OT  - Nanoparticles and microparticles
OT  - Osteoarthritis therapeutics
COIS- Declaration of Competing Interest Gregor Bordon and Oliver Distler declare that 
      they have no known competing financial interests or personal relationships that 
      could have appeared to influence the work reported in this paper. Francis 
      Berenbaum is founder and CMO of 4Moving Biotech and has consulted for 4P Pharma, 
      AstraZeneca, Cellprothera, Grunenthal, GSK, Medivir, Novartis, Pfizer, Lilly, 
      Servier. Paola Luciani has consulted and received research funding from Lipoid 
      GmbH, Sanofi-Aventis Deutschland and DSM Nutritional Products Ltd.
EDAT- 2023/11/09 00:42
MHDA- 2023/11/15 06:42
CRDT- 2023/11/08 18:10
PHST- 2023/07/06 00:00 [received]
PHST- 2023/10/29 00:00 [revised]
PHST- 2023/10/31 00:00 [accepted]
PHST- 2023/11/15 06:42 [medline]
PHST- 2023/11/09 00:42 [pubmed]
PHST- 2023/11/08 18:10 [entrez]
AID - S0753-3322(23)01617-7 [pii]
AID - 10.1016/j.biopha.2023.115819 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2023 Dec;168:115819. doi: 10.1016/j.biopha.2023.115819. Epub 
      2023 Nov 6.